<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Fluoroquinolones
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Fluoroquinolones
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Fluoroquinolones
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David C Hooper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen B Calderwood, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluoroquinolones are highly effective antibiotics with many advantageous pharmacokinetic properties including high oral bioavailability, large volume of distribution, and broad-spectrum antimicrobial activity. With widespread use, antimicrobial resistance to fluoroquinolones has grown. In addition, fluoroquinolones carry risk of serious adverse effects (eg,
         <em>
          Clostridioides difficile
         </em>
         infection, tendinopathy, neuropathy) and have multiple drug-drug interactions. Thus, fluoroquinolone use is typically reserved for cases in which the benefits clearly outweigh the risks.
        </p>
        <p>
         The spectrum of activity, mechanisms of action and resistance, important resistance patterns, and adverse effects of commonly available fluoroquinolones (ie,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          delafloxacin
         </a>
         ) will be reviewed here. Detailed information on pharmacokinetics, pharmacodynamics, and drug interactions can be found by using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p class="headingAnchor" id="H2024123323">
         <span class="h1">
          BENEFITS AND RISKS OF USE
         </span>
        </p>
        <p class="headingAnchor" id="H1738667275">
         <span class="h2">
          Restriction of use for uncomplicated infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, we find that the risks of fluoroquinolone use outweigh the benefits for the treatment of uncomplicated infections such as acute rhinosinusitis, uncomplicated cystitis, and acute bronchitis. Antibiotics are either not indicated for these conditions or alternate agents with lower toxicity profiles are usually available for their treatment. (See
         <a class="medical medical_review" href="/z/d/html/83012.html" rel="external">
          "Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">
          "Acute simple cystitis in adult and adolescent females"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6870.html" rel="external">
          "Acute bronchitis in adults"
         </a>
         .)
        </p>
        <p>
         This approach is in line with recommendations from the US Food and Drug Administration (FDA) derived from their 2016 safety review, which showed that systemic fluoroquinolone use is associated with uncommon but potentially permanent and disabling adverse effects involving the musculoskeletal and nervous systems [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Adverse effects'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2581853581">
         <span class="h2">
          Use for more severe infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         When treating more severe infections, we weigh the benefits and risks of fluoroquinolone use in each individual patient.
        </p>
        <p>
         For the majority, fluoroquinolones are well tolerated. The most common adverse effects are mild and include gastrointestinal upset, headaches, dizziness, or a transient change in mood or sleep. Although their exact incidence is unknown, gastrointestinal and central nervous system adverse effects are estimated to be three times more common with fluoroquinolones when compared with other antibiotics [
         <a href="#rid2">
          2
         </a>
         ]. The incidence of
         <em>
          C. difficile
         </em>
         infection also appears to be higher with fluoroquinolone use when compared with some other antibiotics [
         <a href="#rid3">
          3,4
         </a>
         ]. Thus, when equally efficacious and narrower spectrum options are available, we tend to select them over fluoroquinolones.
        </p>
        <p>
         Less common but potentially severe adverse effects include tendinopathies and tendon rupture, peripheral neuropathy, QT interval prolongation, and putatively aortic dissection and rupture. Rarely, tendinopathies and neuropathies can be permanent and/or disabling; thus, we try to avoid fluoroquinolones in patients with known tendinopathies and neuropathies or in those at risk. Similarly, we avoid fluoroquinolone use in patients with prolonged QT intervals or in patients taking other medications that prolong the QT interval. (See
         <a class="local">
          'Tendinopathy'
         </a>
         below and
         <a class="local">
          'Peripheral neuropathy'
         </a>
         below and
         <a class="local">
          'QT interval prolongation'
         </a>
         below.)
        </p>
        <p>
         Aortic dissection and rupture is a putative, but potentially devastating, adverse effect associated with fluoroquinolone use. Although the putative risk is small, the FDA warns against fluoroquinolone use in patients with known aortic aneurysms and those with risk factors for aneurysm such as Marfan syndrome, Ehlers Danlos syndrome, peripheral atherosclerotic vascular diseases, uncontrolled hypertension, and/or advanced age [
         <a href="#rid5">
          5
         </a>
         ]. The risk-benefit ratio clearly varies among such individuals. As an example, for an older patient with severe community-acquired pneumonia, the benefits of fluoroquinolone use may outweigh the small potential risk of aortic aneurysm rupture. By contrast, the risk-benefit ratio is likely greater for an individual with a known aneurysm and a questionable indication for fluoroquinolone use. (See
         <a class="local">
          'Aortic aneurysm and dissection'
         </a>
         below.)
        </p>
        <p>
         Fluoroquinolones also interact with a variety of other drugs, which need be taken into account when prescribing (see
         <a class="local">
          'Drug interactions'
         </a>
         below). Additional uncommon adverse effects are also discussed below. (See
         <a class="local">
          'Adverse effects'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1378512600">
         <span class="h2">
          Special populations
         </span>
        </p>
        <p class="headingAnchor" id="H4231855561">
         <span class="h3">
          Pregnancy and breastfeeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluoroquinolones should generally be avoided during pregnancy and lactation unless a safer alternative is not available. In animal models, fluoroquinolone use during pregnancy has been associated with cartilage and bone toxicity in developing fetuses [
         <a href="#rid6">
          6-9
         </a>
         ]. While similar effects have not been observed in humans, available data are limited and follow-up times generally do not exceed time of birth [
         <a href="#rid10">
          10,11
         </a>
         ]. Reassuringly, in one meta-analysis of observational studies evaluating over 2800 pregnant women exposed to fluoroquinolones, no differences in congenital malformations, spontaneous abortion, or prematurity were detected when compared with unexposed pregnant women [
         <a href="#rid11">
          11
         </a>
         ]. While a small decrease in the live birth rate was detected among pregnant women exposed to fluoroquinolones when compared with controls in this study, this appears to correlate with an increase in elective pregnancy terminations, possibly due to a misperceived risk to the newborn.
        </p>
        <p class="headingAnchor" id="H2573615184">
         <span class="h3">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine use of systemic fluoroquinolones should be avoided in children due to the potential risk of musculoskeletal toxicity. However, it is reasonable to use a systemic fluoroquinolone in children when no safe or effective alternative exists or when parenteral therapy can be avoided by using an oral fluoroquinolone [
         <a href="#rid12">
          12-17
         </a>
         ]. This approach is consistent with recommendations from the American Academy of Pediatrics [
         <a href="#rid12">
          12
         </a>
         ]. FDA-approved uses in children are limited and include treatment of complicated urinary tract infections and pyelonephritis as well as treatment and prevention of inhalation anthrax.
        </p>
        <p>
         The concern over musculoskeletal toxicity is based on the association between fluoroquinolones and tendinopathies as well as studies in juvenile animals, which have demonstrated a dose- and duration-dependent association with erosive arthropathy in weight-bearing joints with fluoroquinolone use [
         <a href="#rid12">
          12
         </a>
         ]. Available clinical trial data suggest that adverse musculoskeletal events are usually mild and not long term. As an example, in a retrospective cohort study evaluating 2233 children, reports of musculoskeletal toxicity were higher among children who received
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         when compared with a non-fluoroquinolone antibiotic (3.4 versus 1.8 percent) over a one-year period [
         <a href="#rid18">
          18
         </a>
         ]. Arthralgia was the most common musculoskeletal adverse event, reported in over 80 percent of symptomatic children in both groups. Children who had persisting musculoskeletal adverse events during the first year of follow-up were requested to enroll in four additional years of follow-up [
         <a href="#rid19">
          19
         </a>
         ]. Of children identified with a musculoskeletal adverse event during years 2 through 5 following treatment, the number that were considered "possibly related" to drug therapy was equal for both groups (1 of 1340 in the levofloxacin group; 1 of 893 in the comparator group). No musculoskeletal adverse event was considered "likely related" to levofloxacin.
        </p>
        <p class="headingAnchor" id="H1815524305">
         <span class="h3">
          Patients with myasthenia gravis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluoroquinolones should be avoided in individuals with myasthenia gravis because they have neuromuscular-blocking activity that may precipitate myasthenic crises [
         <a href="#rid20">
          20
         </a>
         ]. Postmarketing reports have included death and respiratory failure requiring mechanical ventilation in patients with myasthenia gravis receiving fluoroquinolones. The label carries a boxed warning from the FDA advising against use in this population [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1859926292">
         <span class="h1">
          MECHANISM OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluoroquinolones are bactericidal antibiotics that directly inhibit bacterial deoxyribonucleic acid (DNA) synthesis [
         <a href="#rid22">
          22,23
         </a>
         ]. All fluoroquinolones bind to complexes of DNA with each of two enzymes that are essential for DNA replication, DNA gyrase and DNA topoisomerase IV, and this binding generates DNA cleavage. The potency with which fluoroquinolones inhibit one enzyme or the other varies among bacterial species. In general, fluoroquinolone generation of DNA cleavage complexes results in cessation of DNA replication, DNA damage, and, ultimately, cell death.
        </p>
        <p class="headingAnchor" id="H2783446913">
         <span class="h1">
          PHARMACOKINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         High oral bioavailability and a large volume of distribution are key pharmacokinetic properties of most fluoroquinolones  (
         <a class="graphic graphic_table graphicRef72974" href="/z/d/graphic/72974.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Each fluoroquinolone is absorbed from the upper gastrointestinal tract [
         <a href="#rid24">
          24-28
         </a>
         ].
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">
          ofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         , and
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          delafloxacin
         </a>
         all have oral and intravenous formulations that allow direct estimates of oral bioavailability, with values of 59 percent for delafloxacin, 70 percent for ciprofloxacin, 86 percent for moxifloxacin, and &gt;95 percent for ofloxacin and levofloxacin [
         <a href="#rid28">
          28,29
         </a>
         ].
         <a class="drug drug_general" data-topicid="9710" href="/z/d/drug information/9710.html" rel="external">
          Norfloxacin
         </a>
         has an oral formulation only, and its estimated bioavailability is approximately 30 to 40 percent.
        </p>
        <p>
         Peak concentrations in serum are usually attained within one to three hours of administering an oral dose. Food does not substantially reduce fluoroquinolone absorption but may delay the time to reach peak serum concentrations [
         <a href="#rid30">
          30,31
         </a>
         ]. However, dairy, antacids, multivitamins containing zinc, certain medications (eg,
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          sucralfate
         </a>
         ), and other sources of divalent cations (aluminum, magnesium, calcium) can substantially decrease absorption (presumably by formation of cation-quinolone complexes). Concurrent use should be avoided or these substances should be given several hours apart from the fluoroquinolone in order to avoid their interaction [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         The volumes of distribution of quinolones are high and, in most cases, exceed the volume of total body water, indicating accumulation in some tissues. Concentrations in prostate tissue, stool, bile, lung, and neutrophils as well as macrophages usually exceed serum concentrations. Concentrations in urine and kidney tissue are high for the quinolones with a major renal route of elimination (all except
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ). Concentrations of quinolones in saliva, prostatic fluid, bone, and cerebrospinal fluid are usually lower than drug concentrations in serum.
        </p>
        <p>
         Detailed information on metabolism  (
         <a class="graphic graphic_table graphicRef72974" href="/z/d/graphic/72974.html" rel="external">
          table 1
         </a>
         ), dose adjustments, and other pharmacokinetic properties can be found using the Lexicomp drug information monographs included within UpToDate. (See
         <a class="drug drug_general" href="/z/d/drug information/9053.html" rel="external">
          "Ciprofloxacin (systemic): Drug information"
         </a>
         and
         <a class="drug drug_general" href="/z/d/drug information/10214.html" rel="external">
          "Levofloxacin (systemic): Drug information"
         </a>
         and
         <a class="drug drug_general" href="/z/d/drug information/9845.html" rel="external">
          "Moxifloxacin (systemic): Drug information"
         </a>
         and
         <a class="drug drug_general" href="/z/d/drug information/113710.html" rel="external">
          "Delafloxacin: Drug information"
         </a>
         and
         <a class="drug drug_general" href="/z/d/drug information/9892.html" rel="external">
          "Ofloxacin (systemic): Drug information"
         </a>
         and
         <a class="drug drug_general" href="/z/d/drug information/9710.html" rel="external">
          "Norfloxacin (United States: Not available): Drug information"
         </a>
         and
         <a class="drug drug_general" href="/z/d/drug information/8760.html" rel="external">
          "Gemifloxacin (United States: Not available): Drug information"
         </a>
         and
         <a class="drug drug_general" href="/z/d/drug information/8928.html" rel="external">
          "Gatifloxacin: Drug information"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H321404865">
         <span class="h1">
          SPECTRUM OF ACTIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluoroquinolones are broad-spectrum antibiotics with potent activity against aerobic, enteric gram-negative bacilli and many common respiratory pathogens. In addition, some fluoroquinolones are active against
         <em>
          Pseudomonas
         </em>
         species, selected gram-positive organisms, anaerobes, and mycobacteria. The relative potency against specific pathogens within these categories varies among fluoroquinolones. Because resistance to fluoroquinolones is common, knowledge of local epidemiology is important when selecting an antibiotic. (See
         <a class="local">
          'Antimicrobial resistance'
         </a>
         below.)
        </p>
        <p>
         Fluoroquinolones are also important for the treatment of less common infections including tuberculosis, non-tuberculous mycobacterial infections, and anthrax.
        </p>
        <p>
         Although some fluoroquinolones have activity against certain gram-positive organisms and anaerobes, clinical experience with their use for these organisms is limited and their potency is often less than that of other antibiotics. Thus, fluoroquinolones are generally not used as first-line agents for susceptible organisms within these categories.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         – Ciprofloxacin primarily targets and has the greatest activity against aerobic, enteric gram-negative bacilli (eg, Enterobacterales, including
         <em>
          Escherichia coli, Klebsiella
         </em>
         spp,
         <em>
          Proteus
         </em>
         spp), as well as
         <em>
          Pseudomonas
         </em>
         <em>
          aeruginosa
         </em>
         . This spectrum of activity makes ciprofloxacin a great option for intra-abdominal infections and other infections caused by enteric bacteria. Although ciprofloxacin also has potent activity against aerobic gram-negative respiratory pathogens (eg,
         <em>
          H. influenzae
         </em>
         ,
         <em>
          M. catarrhalis
         </em>
         ), it has limited to no activity against gram-positive organisms (eg,
         <em>
          S. pneumoniae, Staphylococcus aureus
         </em>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          Levofloxacin
         </a>
         – Levofloxacin has activity against gram-positive organisms (eg,
         <em>
          Streptococcus pneumoniae, Staphylococcus aureus,
         </em>
         some strains of coagulase-negative staphylococci) and reduced, but still adequate activity, against aerobic, enteric gram-negative organisms and
         <em>
          P. aeruginosa
         </em>
         . Levofloxacin is also active against most common respiratory pathogens, including
         <em>
          Streptococcus pneumoniae, Haemophilus influenzae
         </em>
         ,
         <em>
          Moraxella catarrhalis
         </em>
         ,
         <em>
         </em>
         and intracellular or cell wall-deficient bacteria (ie,
         <em>
          Legionella
         </em>
         spp,
         <em>
          Mycoplasma
         </em>
         spp,
         <em>
         </em>
         and
         <em>
          Chlamydia
         </em>
         <em>
          pneumoniae
         </em>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          Moxifloxacin
         </a>
         – Moxifloxacin has activity against gram-positive organisms (eg,
         <em>
          Streptococcus pneumoniae, Staphylococcus aureus, s
         </em>
         ome strains of coagulase-negative staphylococci) and reduced, but still adequate activity, against aerobic, enteric gram-negative organisms (eg, Enterobacterales, including
         <em>
          Escherichia coli, Klebsiella
         </em>
         spp,
         <em>
          Proteus
         </em>
         spp). Moxifloxacin is less active than
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         against
         <em>
          Pseudomonas aeruginosa,
         </em>
         <em>
          Providencia s
         </em>
         pp,
         <em>
          Proteus s
         </em>
         pp, and
         <em>
          Serratia marcescens
         </em>
         and is generally not used to treat these organisms. Moxifloxacin is also active against most common respiratory pathogens, including
         <em>
          Streptococcus pneumoniae, Haemophilus influenzae,
         </em>
         <em>
          Moraxella catarrhalis, a
         </em>
         nd intracellular or cell wall-deficient bacteria (ie,
         <em>
          Legionella s
         </em>
         pp,
         <em>
          Mycoplasma
         </em>
         spp,
         <em>
          a
         </em>
         nd
         <em>
          Chlamydia pneumoniae)
         </em>
         . Additionally, moxifloxacin has activity against some anaerobes and is most active against mycobacteria compared with other fluoroquinolones. Given its overall spectrum of activity, although data are limited, moxifloxacin appears to be similarly effective as
         <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">
          ampicillin-sulbactam
         </a>
         for anaerobic lung infections (eg, aspiration pneumonia or lung abscess) [
         <a href="#rid33">
          33
         </a>
         ] and is the only fluoroquinolone that has sufficient activity against anaerobic bacteria for clinical use. Resistance among
         <em>
          Bacteroides
         </em>
         species limits its use for the treatment of intra-abdominal infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          Delafloxacin
         </a>
         – Delafloxacin has activity against gram-positive organisms (eg,
         <em>
          Streptococcus pneumoniae, Staphylococcus aureus,
         </em>
         some strains of coagulase-negative staphylococci) and reduced, but still adequate activity, against aerobic, enteric gram-negative organisms (eg, Enterobacterales, including
         <em>
          Escherichia coli, Klebsiella
         </em>
         spp,
         <em>
          Proteus
         </em>
         spp) and
         <em>
          P. aeruginosa
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          Delafloxacin
         </a>
         is the only fluoroquinolone with reliable activity against methicillin-resista
         <em>
          nt Staphylococcus aureus
         </em>
         (MRSA). However, clinical experience with delafloxacin is limited. Delafloxacin also has activity against anaerobes in vitro [
         <a href="#rid34">
          34
         </a>
         ], but in vivo data are lacking. (See
         <a class="medical medical_review" href="/z/d/html/5520.html" rel="external">
          "Anaerobic bacterial infections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other antimicrobial activity of fluoroquinolones
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Enterococci – Although some fluoroquinolones have in vitro activity against enterococci, they are generally not used for the treatment of enterococcal infections because achievable serum concentrations are frequently close to the minimum inhibitory concentrations and efficacy data are limited. (See
         <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">
          "Treatment of enterococcal infections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          Mycobacterium tuberculosis
         </em>
         – Fluoroquinolones also have excellent activity in vitro against
         <em>
          Mycobacterium tuberculosis
         </em>
         and are used as second-line agents in the setting of resistance and/or intolerance to first-line agents. In general,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         and
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         are preferred over other fluoroquinolones because of their greater potency. (See
         <a class="medical medical_review" href="/z/d/html/488.html" rel="external">
          "Antituberculous drugs: An overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nontuberculous mycobacteria – Fluoroquinolones are also active against many nontuberculous mycobacteria including
         <em>
          M. fortuitum
         </em>
         ,
         <em>
          M. kansasii
         </em>
         , and some strains of
         <em>
          M. chelonae
         </em>
         .
         <em>
         </em>
         Activity against
         <em>
          M. avium
         </em>
         complex is fair to poor.
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          Moxifloxacin
         </a>
         and
         <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">
          ofloxacin
         </a>
         are active against
         <em>
          M. leprae
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">
          "Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16520.html" rel="external">
          "Leprosy: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other atypical bacteria – Fluoroquinolones are among first-line options for the treatment of susceptible infections caused by
         <em>
          Bacillus anthracis, Francisella tularensis,
         </em>
         and
         <em>
          Salmonella enterica
         </em>
         Serovar Typhi (typhoid fever). Specific recommendations vary by site and severity of infection. (See
         <a class="medical medical_review" href="/z/d/html/15309.html" rel="external">
          "Treatment of anthrax"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3141.html" rel="external">
          "Tularemia: Clinical manifestations, diagnosis, treatment, and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2712.html" rel="external">
          "Enteric (typhoid and paratyphoid) fever: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          ANTIMICROBIAL RESISTANCE
         </span>
        </p>
        <p class="headingAnchor" id="H388929178">
         <span class="h2">
          Mechanisms of resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resistance to quinolones may occur via mutations in bacterial chromosomal genes or via acquisition of resistance genes on plasmids.
        </p>
        <p>
         Mutations in chromosomal genes occur in genes that [
         <a href="#rid35">
          35
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Encode the subunits of DNA gyrase and topoisomerase IV (altered target mechanism)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regulate the expression of cytoplasmic membrane efflux pumps or proteins that constitute outer membrane diffusion channels (altered permeation mechanism)
        </p>
        <p>
        </p>
        <p>
         Major plasmid-mediated resistance mechanisms include [
         <a href="#rid36">
          36-42
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Qnr proteins, which protect DNA gyrase and topoisomerase IV from quinolone activity
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluoroquinolone-modifying enzymes (encoded by an aminoglycoside acetyltransferase variant gene [
         <em>
          AAC(6′)-Ib-cr
         </em>
         ]), which acetylates fluoroquinolones and reduces their activity
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Efflux pumps (encoded by
         <em>
          qepA
         </em>
         and
         <em>
          oqxAB
         </em>
         genes), which pump fluoroquinolones (particularly
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         and
         <a class="drug drug_general" data-topicid="9710" href="/z/d/drug information/9710.html" rel="external">
          norfloxacin
         </a>
         ) out of the cell
        </p>
        <p>
        </p>
        <p>
         Plasmid-mediated resistance mechanisms typically confer low-level resistance. However, high-level resistance can result when plasmid-mediated mechanisms accumulate or co-occur with chromosomal mutations. The likelihood of developing resistance is believed to be related to the intensity and duration of antibiotic therapy. As an example, ≥5 days of fluoroquinolone exposure was associated with significant resistance in an in vitro model [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Plasmid-mediated resistance mechanisms can confer resistance to other antimicrobial classes directly or because they are linked to other drug-resistance genes encoded on the same plasmid.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Important resistance patterns
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resistance to fluoroquinolones is common, and rates are growing worldwide among many targeted bacteria. Thus, fluoroquinolone use may be precluded or limited for certain indications unless susceptibility is documented such as the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sexually transmitted infections, particularly with
         <em>
          Neisseria gonorrhoeae
         </em>
         (see
         <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">
          "Treatment of uncomplicated gonorrhea (
          <i>
           Neisseria gonorrhoeae
          </i>
          infection) in adults and adolescents", section on 'Fluoroquinolones'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinary tract infections (see
         <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">
          "Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">
          "Acute simple cystitis in adult and adolescent females", section on 'Management'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          P. aeruginosa
         </em>
         infections (see
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Typhoid and paratyphoid (see
         <a class="medical medical_review" href="/z/d/html/2712.html" rel="external">
          "Enteric (typhoid and paratyphoid) fever: Treatment and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2712.html" rel="external">
          "Enteric (typhoid and paratyphoid) fever: Treatment and prevention", section on 'Antimicrobial resistance'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infections with
         <em>
          Shigella
         </em>
         spp and
         <em>
          Campylobacter
         </em>
         spp (see
         <a class="medical medical_review" href="/z/d/html/2701.html" rel="external">
          "Shigella infection: Treatment and prevention in adults", section on 'Antibiotic resistance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2715.html" rel="external">
          "Campylobacter infection: Clinical manifestations, diagnosis, and treatment", section on 'Resistance'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Fluoroquinolone resistance is relatively uncommon among
         <em>
          S. pneumoniae, H. influenzae
         </em>
         , and
         <em>
          M. catarrhalis.
         </em>
         (See
         <a class="medical medical_review" href="/z/d/html/7028.html" rel="external">
          "Resistance of
          <i>
           Streptococcus pneumoniae
          </i>
          to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17122.html" rel="external">
          "
          <i>
           Moraxella catarrhalis
          </i>
          infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8048.html" rel="external">
          "Epidemiology, clinical manifestations, diagnosis, and treatment of
          <i>
           Haemophilus influenzae
          </i>
          "
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          ADVERSE EFFECTS
         </span>
        </p>
        <p class="headingAnchor" id="H696429408">
         <span class="h2">
          General considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluoroquinolones are generally safe and well tolerated. However, rare but severe adverse events have been reported, leading to restrictions in their use [
         <a href="#rid1">
          1
         </a>
         ] and, in some cases, their removal from the market [
         <a href="#rid44">
          44-47
         </a>
         ].
        </p>
        <p>
         Much of the data regarding adverse effects are derived from passive reporting systems and observational studies, which are prone to confounding. In some cases, uncommon side effects were only recognized with more extensive clinical use after regulatory approval. Because safety and tolerability are best assessed in randomized trials, our knowledge of adverse effects associated with fluoroquinolone use continues to evolve.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          Delafloxacin
         </a>
         is structurally designed to have a lower adverse effect profile, particularly for central nervous system events and phototoxicity [
         <a href="#rid48">
          48
         </a>
         ]. Randomized trial data suggest that treatment-related adverse events may be less common with delafloxacin when compared with other fluoroquinolones [
         <a href="#rid49">
          49
         </a>
         ]. However, only limited numbers of patients have thus far been treated with delafloxacin, and long-term data are lacking.
        </p>
        <p class="headingAnchor" id="H1969391291">
         <span class="h2">
          Gastrointestinal
         </span>
        </p>
        <p class="headingAnchor" id="H1806052234">
         <span class="h3">
          Gastritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common adverse effect associated with fluoroquinolone use is transient and mild gastrointestinal upset (eg, anorexia, nausea, vomiting, or abdominal discomfort). Diarrhea is less common.
        </p>
        <p class="headingAnchor" id="H2466852071">
         <span class="h3">
          C. difficile-associated disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of their broad-spectrum, fluoroquinolones may confer greater risk of
         <em>
          C. difficile
         </em>
         -associated disease when compared with some other antibiotics [
         <a href="#rid3">
          3,4
         </a>
         ]. Reductions in fluoroquinolone prescriptions have been associated with declines in
         <em>
          C. difficile
         </em>
         rates both in the community and in health care institutions [
         <a href="#rid50">
          50-52
         </a>
         ].
        </p>
        <p>
         Certain epidemic strains of
         <em>
          C. difficile
         </em>
         (ie, NAP1/BI/027) are fluoroquinolone resistant; use of fluoroquinolones during outbreaks caused by such strains has been a risk factor for the development of
         <em>
          C. difficile-
         </em>
         associated disease
         <em>
         </em>
         [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in adults: Epidemiology, microbiology, and pathophysiology"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3997515951">
         <span class="h3">
          Hepatoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         As a class, fluoroquinolones are associated with low risk of mild elevation of aminotransferase levels. Among commonly used fluoroquinolones (ie,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ), severe hepatic failure is rare but reported [
         <a href="#rid54">
          54-58
         </a>
         ].
        </p>
        <p>
         In a population-wide propensity-matched retrospective study of all Swedish patients aged 40 to 85 years, receipt of an oral fluoroquinolone was associated with a higher risk of acute liver injury compared with those who received
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         (hazard ratio [HR] 2.32, 95% CI 1.01-5.35), although absolute incidence was only 2.98 and 1.27 per 10,000 person-years, respectively [
         <a href="#rid59">
          59
         </a>
         ]. A similar increase in risk of hepatotoxicity has also been observed in multiple case control studies [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
         Trovafloxacin warrants mention because it was removed from the market worldwide for its association with fatal hepatoxicity [
         <a href="#rid46">
          46,47
         </a>
         ].
         <a class="drug drug_general" data-topicid="8928" href="/z/d/drug information/8928.html" rel="external">
          Gatifloxacin
         </a>
         has the second strongest association with hepatoxicity; it is no longer available in the United States, and worldwide availability is limited.
        </p>
        <p class="headingAnchor" id="H2370258977">
         <span class="h2">
          Neurologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurologic adverse effects are among the most common adverse effects associated with fluoroquinolones [
         <a href="#rid2">
          2
         </a>
         ]. Most neurologic adverse effects are mild, such as headache, dizziness, or transient change in mood or sleep patterns. Less commonly, more serious central nervous system adverse effects can occur, ranging from delirium to hallucination to seizures. The peripheral nervous system can also be affected; peripheral neuropathy predominates.
        </p>
        <p class="headingAnchor" id="H1736666902">
         <span class="h3">
          Altered mental status
         </span>
         <span class="headingEndMark">
          —
         </span>
         The labels of all systemic fluoroquinolones include US Food and Drug Administration (FDA) warnings about the risk of delirium, memory impairment, disorientation, agitation, and disturbances in attention. Such adverse effects have been reported after a single fluoroquinolone dose, and the offending drug should be stopped if they occur [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2962520273">
         <span class="h3">
          Peripheral neuropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peripheral neuropathy is an uncommon but well-described adverse effect of fluoroquinolone use [
         <a href="#rid63">
          63,64
         </a>
         ]. Peripheral neuropathy can occur at any time during treatment with a fluoroquinolone and can last for months to years after the drug is stopped or be permanent. In reported cases, the onset of peripheral neuropathy was rapid, often within a few days.
        </p>
        <p>
         Symptoms of peripheral neuropathy may include pain, burning, tingling, numbness, weakness, or a change in sensation to light, touch, pain, temperature, or the sense of body position. If symptoms of peripheral neuropathy develop while receiving a fluoroquinolone, the fluoroquinolone should be stopped, and the patient should be switched to an antibiotic from a different class, unless the benefit of continuing the fluoroquinolone outweighs the risk. Generally, the management of fluoroquinolone-associated peripheral neuropathy is similar to the management of other drug-induced neuropathies, which includes stopping the offending agent and providing symptomatic care. (See
         <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">
          "Overview of polyneuropathy", section on 'Management'
         </a>
         .)
        </p>
        <p>
         Although the precise incidence is unknown, in a case-control study of men aged 45 to 80 years, current users of fluoroquinolones were at a higher risk of developing peripheral neuropathy than controls (rate ratio [RR] 1.83, 95% CI 1.49-2.27) [
         <a href="#rid63">
          63
         </a>
         ]. Similar findings were reported in another nested case-control study comparing 5357 cases of peripheral neuropathy to matched controls [
         <a href="#rid65">
          65
         </a>
         ]. Risk was highest among men and patients &gt;60 years old; risk increased by approximately 3 percent with each day of exposure and persisted for 180 days. The number needed to harm for a 10-day course was 152,083 patients (95% CI 117,742-202,778).
        </p>
        <p>
         The exact mechanism by which peripheral neuropathy occurs remains unknown [
         <a href="#rid66">
          66
         </a>
         ]. Hypotheses include direct nerve inflammation with or without ischemia caused by toxic metabolite and free radical accumulation [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4143898527">
         <span class="h3">
          Other adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other neurologic adverse effects are uncommon and include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizure
         </strong>
         – Seizures are very rare complications of fluoroquinolone use. In some cases, seizures may result from
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         accumulation or from the ability of theophylline and nonsteroidal anti-inflammatory drugs to augment fluoroquinolone-mediated displacement of gamma-aminobutyric acid from its receptors [
         <a href="#rid68">
          68-70
         </a>
         ]. (See
         <a class="local">
          'Drug interactions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pseudotumor cerebri
         </strong>
         – Fluoroquinolone use has also been associated with secondary pseudotumor cerebri syndrome, as illustrated by the findings of a case-control study evaluating health care records from over six million patients [
         <a href="#rid71">
          71
         </a>
         ]. Compared with nonuse, fluoroquinolone use within 15 or 30 days of diagnosis increased the risk of developing secondary pseudotumor cerebri syndrome (adjusted rate ratios for 15 days 5.67, 95% CI 2.72-11.83). Although the overall rate of the disorder was low, estimated at about 2 per 100,000 overall and 1 in 166,000 due to fluoroquinolones, clinicians should be aware of this potential risk in patients with characteristic symptoms (eg, headache, tinnitus, diplopia).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myasthenia gravis exacerbations
         </strong>
         – Fluoroquinolones have neuromuscular-blocking activity and may exacerbate muscle weakness in individuals with myasthenia gravis [
         <a href="#rid20">
          20
         </a>
         ]. Postmarketing reports have included death and respiratory failure requiring mechanical ventilation in patients with myasthenia gravis receiving fluoroquinolones. Thus, fluoroquinolones should be avoided in individuals with myasthenia gravis. (See
         <a class="medical medical_review" href="/z/d/html/5125.html" rel="external">
          "Myasthenic crisis", section on 'Precipitants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3768405951">
         <span class="h2">
          Cardiovascular
         </span>
        </p>
        <p class="headingAnchor" id="H2707133439">
         <span class="h3">
          QT interval prolongation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluoroquinolones can prolong the QT interval by inhibiting cardiac KCHN2 potassium voltage-gated channels, potentially leading to torsades de pointes (a life-threatening arrhythmia) [
         <a href="#rid72">
          72
         </a>
         ]. When safe and effective alternatives are available, we avoid fluoroquinolone use for patients taking other QT-prolonging drugs and patients with long QT syndromes or other significant risk factors for arrhythmia  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Available clinical data suggest that, among available fluoroquinolones,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         has the highest association with QT interval prolongation, arrhythmia, and cardiovascular mortality, followed by
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         and then
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         [
         <a href="#rid73">
          73-76
         </a>
         ].
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          Delafloxacin
         </a>
         , which came to market in 2018, has not been associated with QT interval prolongation, but clinical experience is limited [
         <a href="#rid28">
          28,77
         </a>
         ]. Sparfloxacin, grepafloxacin, and
         <a class="drug drug_general" data-topicid="8928" href="/z/d/drug information/8928.html" rel="external">
          gatifloxacin
         </a>
         each had strong associations with QT interval prolongation [
         <a href="#rid78">
          78
         </a>
         ]. However, these agents have either been removed from the market or have limited availability.
        </p>
        <p>
         In a meta-analysis of five large observational studies and one randomized trial evaluating &gt;7 million patients, fluoroquinolone use was associated with an increased risk of arrhythmia (odds ratio [OR] 1.85, 95% CI 1.22-2.81) when compared with either placebo or other antibiotic use [
         <a href="#rid76">
          76
         </a>
         ]. Concordantly, an increased risk of cardiovascular mortality was detected in a meta-analysis of one randomized trial and two observational studies evaluating over three million patients (OR 1.71, 95% CI 1.39-2.09). Based on a network meta-analysis of clinically available fluoroquinolones, the risk of arrhythmia was highest with
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         use followed by
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         and
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         [
         <a href="#rid76">
          76
         </a>
         ]. A similar trend was observed for cardiovascular mortality, although the increase in risk with moxifloxacin when compared with levofloxacin did not reach statistical significance.
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          Delafloxacin
         </a>
         was not evaluated.
        </p>
        <p>
         Because most studies evaluating the effect of fluoroquinolones on the QT interval are observational, they are prone to confounding by indication (eg, fluoroquinolone use for pneumonia carries greater baseline risk of adverse cardiovascular effects than does
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         use for acute sinusitis). In addition, most studies do not account for comorbidities that may augment risk of arrhythmia. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">
          "Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2110851765">
         <span class="h3">
          Aortic aneurysm and dissection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several observational studies have suggested that fluoroquinolone use may be associated with an increased risk of aortic aneurysm or dissection [
         <a href="#rid79">
          79-83
         </a>
         ]. However, the causal role of fluoroquinolones in the development of aortic aneurysms and dissection is unclear.
        </p>
        <p>
         Based on these studies, the FDA issued a warning in December 2018 highlighting this association and recommended avoiding fluoroquinolones in patients with known aortic aneurysms or those with risk factors for aneurysm such as Marfan syndrome, Ehlers Danlos syndrome, peripheral atherosclerotic vascular diseases, uncontrolled hypertension, and/or advanced age [
         <a href="#rid5">
          5
         </a>
         ]. In one nationwide cohort study in Sweden, fluoroquinolone use (360,088 fluoroquinolone treatment episodes) was associated with an increased risk of aortic aneurysm within 60 days from the start of treatment when compared with
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         use (1.2 versus 0.7 cases per 1000 person-years; HR 1.66, 95% CI 1.12-2.46) in propensity-matched controls. The estimated absolute difference was 82 cases of aortic aneurysm or dissection per 1 million treatment episodes [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         The observational nature of this study leaves room for potential confounders (eg, severity of the infection for which the antibiotic was prescribed, smoking status, baseline blood pressure). If a causal role for fluoroquinolones and aortic aneurysm or dissection exists, the absolute risk is small and likely limited to individuals with predisposing risk factors. Whether preferentially avoiding fluoroquinolones in patients with any risk factor for aortic aneurysm or dissection (eg, hypertension or older age) versus those with strong risk factors (eg, known aneurysm) provides benefit is unclear. When considering fluoroquinolone use, we take this uncertainty into account and weigh the overall risk-benefit ratio in each patient.
        </p>
        <p class="headingAnchor" id="H3025039139">
         <span class="h2">
          Other adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aortic and mitral valve regurgitation have been associated with fluoroquinolone use in a single large observational study [
         <a href="#rid84">
          84
         </a>
         ]. However, whether this association is causal is uncertain. In a nested case-control study of &gt;135,000 patients extracted from the United States PharMetrics Plus database, current fluoroquinolone use was associated with an increased risk of aortic or mitral regurgitation when compared with
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         (RR 2.40, 95% CI 1.82-3.16) and
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         (RR 1.75, 95% CI 1.34-2.29). No increase in risk was detected for past fluoroquinolone use. Patients with valvular regurgitation also had higher rates of coronary artery disease, heart failure, and atrial fibrillation, suggesting that there may be residual confounding in the analysis. Additional study is needed to confirm or refute these findings.
        </p>
        <p class="headingAnchor" id="H2057035294">
         <span class="h2">
          Musculoskeletal
         </span>
        </p>
        <p class="headingAnchor" id="H1492216857">
         <span class="h3">
          Tendinopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluoroquinolone use has been associated with a broad range of tendinopathies, including tendon rupture [
         <a href="#rid85">
          85-91
         </a>
         ]. The Achilles tendon is most often affected, although any tendon can be involved [
         <a href="#rid90">
          90,92
         </a>
         ]. Thus, when prescribing a fluoroquinolone, we advise patients to discontinue the medication if any sign of tendinopathy develops (ie, pain, swelling). In addition, we generally advise patients to avoid exercise, contact their physician for evaluation, and transition to a non-fluoroquinolone antibiotic when appropriate. This approach is consistent with recommendations from the FDA [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         The incidence of tendinopathies associated with fluoroquinolone use is not well established but is estimated to be low (ie, approximately 3 to 4 cases per 100,000 for the Achilles tendon) [
         <a href="#rid93">
          93,94
         </a>
         ]. Most cases occur early in the course of therapy, with a median of eight days based on case reports [
         <a href="#rid89">
          89,92,94
         </a>
         ].
        </p>
        <p>
         In a cohort study reviewing 28,907 cases of Achilles tendinopathy and 7685 cases of tendon rupture, fluoroquinolone use was associated with increased risk of tendinopathy (OR 4.3, 95% CI 3.2-5.7) and tendon rupture (OR 2.0, 95% CI 1.2-3.3) when compared with other antibiotics [
         <a href="#rid91">
          91
         </a>
         ]. Risk appeared to be higher among persons &gt;60 years old (OR 8.3 versus 1.6), nonobese (OR 7.7 versus 2.4), and those using oral glucocorticoids (OR 9.1 versus 3.2). Kidney, heart, and lung transplantation have been identified as potential additional risk factors [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         It is unclear whether any one fluoroquinolone confers greater risk of tendinopathy over another, although one study demonstrated a higher risk of tendon ruptures with
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         [
         <a href="#rid67">
          67,92,95
         </a>
         ].
        </p>
        <p>
         The mechanisms of fluoroquinolones’ effects on connective tissues are not well understood. Data suggest that tenocyte toxicity is due to local boosting of metalloprotease activity and magnesium chelation from high concentrations of fluoroquinolone accumulated in tendons and possibly other connective tissues [
         <a href="#rid96">
          96,97
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H687882963">
         <span class="h3">
          Arthropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Arthropathy with cartilage erosions and noninflammatory effusions occurs in the weight-bearing joints of juvenile animals given quinolones. Experience with use of quinolones in children has increased, particularly in children with cystic fibrosis given
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         . These children and others receiving nalidixic acid and
         <a class="drug drug_general" data-topicid="9710" href="/z/d/drug information/9710.html" rel="external">
          norfloxacin
         </a>
         have only uncommonly had joint symptoms, which have been reversible [
         <a href="#rid13">
          13,98
         </a>
         ]. Studies to identify subclinical cartilage damage by magnetic resonance imaging of joints of treated children have also been negative [
         <a href="#rid99">
          99
         </a>
         ]. (See
         <a class="local">
          'Children'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1844978571">
         <span class="h2">
          Other adverse effects
         </span>
        </p>
        <p class="headingAnchor" id="H1495528888">
         <span class="h3">
          Dysglycemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluoroquinolones have been associated with both hypoglycemia and hyperglycemia in both diabetic and nondiabetic patients [
         <a href="#rid100">
          100-105
         </a>
         ]. In July 2018, the FDA strengthened its warning about the risk of hypoglycemia associated with systemic fluoroquinolone use, particularly for older adults and those with diabetes mellitus [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Among
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         , moxifloxacin appears to confer the highest risk of both hyperglycemia and hypoglycemia among diabetic patients [
         <a href="#rid100">
          100
         </a>
         ].
         <a class="drug drug_general" data-topicid="8928" href="/z/d/drug information/8928.html" rel="external">
          Gatifloxacin
         </a>
         was withdrawn from the market in the United States and Canada in June 2006 because it was associated with a greater frequency of symptomatic hypoglycemia and hyperglycemia when compared with other fluoroquinolones, including some fatal cases [
         <a href="#rid101">
          101-103
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4012618733">
         <span class="h3">
          Retinal detachment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retinal detachment has been reported with fluoroquinolone use; however, a causal relationship has not been established. Several large observational studies have attempted to assess whether an association between fluoroquinolone use and retinal detachment exists, with conflicting results [
         <a href="#rid79">
          79,106-110
         </a>
         ].
        </p>
        <p>
         A nationwide registry-based cohort study from Denmark that controlled for potential confounders found that neither recent nor current fluoroquinolone use was associated with an increased risk of retinal detachment [
         <a href="#rid107">
          107
         </a>
         ]. Similarly, in a large population-based study in the United States, fluoroquinolone use was not associated with an increased risk of rhegmatogenous retinal detachment or symptomatic retinal breaks [
         <a href="#rid108">
          108
         </a>
         ]. In contrast, a nested case-control study of patients in Canada who visited an ophthalmologist found an increased rate of retinal detachment in patients who were currently receiving an oral fluoroquinolone (3.3 percent of cases versus 0.6 percent of controls; aOR 4.5, 95% CI 3.6-5.7) [
         <a href="#rid106">
          106
         </a>
         ]. The absolute increase in the risk of retinal detachment was 4 per 10,000 person-years. In a case-crossover study using French health care databases that included 27,540 patients with retinal detachment, there was an increased risk for retinal detachment during the 10-day period after being prescribed a fluoroquinolone (aOR 1.46, 95% CI 1.15-1.87) [
         <a href="#rid109">
          109
         </a>
         ]. The risk was increased for both rhegmatogenous (full-thickness; aOR 1.41, 95% CI 1.04-1.92) and exudative (aOR 2.57, 95% CI 1.46-4.53) retinal detachment.
        </p>
        <p>
         Considering all the data above and other reports, the FDA issued an update in May 2017 stating that available data do not support a causal association between fluoroquinolones and retinal detachment [
         <a href="#rid111">
          111
         </a>
         ]. If an association exists, the risk of retinal detachment attributable to fluoroquinolone use is likely small and may be limited to individuals with additional predisposing risk factors.
        </p>
        <p class="headingAnchor" id="H535542058">
         <span class="h3">
          Phototoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some fluoroquinolones carry a small risk of phototoxicity [
         <a href="#rid47">
          47
         </a>
         ]. The effect seems to be most pronounced with older-generation fluoroquinolones (eg, lomefloxacin, sparfloxacin) due to their chemical structures [
         <a href="#rid112">
          112
         </a>
         ]. The risk is lessened with most presently available fluoroquinolones and may be absent for
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          delafloxacin
         </a>
         , which is designed to avoid this adverse effect [
         <a href="#rid113">
          113
         </a>
         ]. Sunscreen containing UVA blockers may offer some protection [
         <a href="#rid114">
          114
         </a>
         ], although this has not been systematically studied.
        </p>
        <p class="headingAnchor" id="H2079626226">
         <span class="h3">
          Hypersensitivity reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Delayed-onset maculopapular rash is the most common type of hypersensitivity reaction to fluoroquinolones, occurring in approximately 2 to 3 percent of patients. Immediate reactions (eg, urticaria, pruritus, angioedema, wheezing, anaphylaxis) are less common but can be life-threatening. In clinical trials, an unusually high occurrence of maculopapular rash (14 percent) was reported in young women receiving
         <a class="drug drug_general" data-topicid="8760" href="/z/d/drug information/8760.html" rel="external">
          gemifloxacin
         </a>
         for seven or more days; biopsies showed no evidence of vasculitis [
         <a href="#rid115">
          115
         </a>
         ]. Persons with a gemifloxacin-associated rash had a higher rate of rash to subsequent
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         (5.9 percent) than those having received placebo [
         <a href="#rid116">
          116
         </a>
         ]. Acute interstitial nephritis also occurs infrequently and has been associated with eosinophiluria but generally not crystalluria [
         <a href="#rid117">
          117
         </a>
         ]. Hypersensitivity reactions to fluoroquinolones are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/83728.html" rel="external">
          "Hypersensitivity reactions to fluoroquinolones"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4146982771">
         <span class="h3">
          Persistent multisystem adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Persistent multisystem symptoms (termed fluoroquinolone-associated disability) have been reported following fluoroquinolone use [
         <a href="#rid118">
          118,119
         </a>
         ]. However, whether fluoroquinolones are causal of such symptoms and what the potential mechanism of action may be is unclear.
        </p>
        <p>
         In 2015, the FDA reviewed its database for all serious adverse events reported in previously healthy persons taking a fluoroquinolone for acute bronchitis, urinary tract infection, and acute rhinosinusitis between 1997 and 2015 [
         <a href="#rid120">
          120
         </a>
         ]. Among 1122 reports, 178 met criteria for events involving two or more body systems and lasting for ≥30 days after stopping the fluoroquinolone. There was an unusually high proportion of direct patient reports for fluoroquinolones when compared with other drugs (85 versus 2 to 6 percent). Three-quarters of reported cases occurred in females and those aged 30 to 59. Almost all had musculoskeletal symptoms; two-thirds each had neuropsychiatric or peripheral nervous system symptoms. Patterns of symptoms and the extent of association were similar among the three most commonly reported (and used) fluoroquinolones,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         . Given the large numbers of fluoroquinolone prescriptions over the study period, the risk of the fluoroquinolone disability syndrome is likely exceedingly low.
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h1">
          DRUG INTERACTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluoroquinolones interact with a variety of other drugs. This section will review the most important or frequent interactions. A complete listing is provided separately for each fluoroquinolone (see appropriate drug information topic reviews by searching on the drug name). In addition, details about specific interactions can be found using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most fluoroquinolones prolong the QT interval and should not be given in combination with other QT-prolonging medications. (See
         <a class="local">
          'QT interval prolongation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         inhibits hepatic cytochrome P450 isoenzyme 1A2, which can impair the elimination of substrate drugs (eg,
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          erlotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          tizanidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         , caffeine, and methylxanthines) [
         <a href="#rid121">
          121,122
         </a>
         ]. Generally, ciprofloxacin should be avoided for patients taking these medications; if coadministration is unavoidable, dosing of substrate drugs should be reduced or levels monitored.
         <a class="drug drug_general" data-topicid="9710" href="/z/d/drug information/9710.html" rel="external">
          Norfloxacin
         </a>
         can also increase theophylline levels, but it is unclear if this is due to cytochrome P450 isoenzyme inhibition. Other fluoroquinolones do not inhibit or induce cytochrome P450 enzymes or xanthine metabolism to a clinically relevant extent  (
         <a class="graphic graphic_table graphicRef72974" href="/z/d/graphic/72974.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsteroidal anti-inflammatory drugs (NSAIDs) may augment the central nervous stimulant effects of fluoroquinolones by displacing neurotransmitter gamma-aminobutyric acid from its receptors, potentially lowering the seizure threshold [
         <a href="#rid69">
          69
         </a>
         ]. The extent to which concurrent use of quinolones with NSAIDs results in central nervous system toxicities is unclear, but patients receiving both classes of drugs should be cautioned about and monitored for these adverse effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         and the long-acting rifamycin,
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         , lower the plasma concentration of
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         [
         <a href="#rid123">
          123,124
         </a>
         ]. This interaction is potentially an important consideration when formulating treatment regimens for tuberculosis and other mycobacterial infections.
        </p>
        <p>
        </p>
        <p>
         Other drug interactions have been studied less extensively.
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         has had effects on the pharmacokinetics of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         . Enoxacin and ciprofloxacin have been shown to reduce the clearance of the less active R-enantiomer of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         but have no clinically important effect on the more active S-enantiomer [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H527964309">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Characteristics of fluoroquinolones
         </strong>
         − Fluoroquinolones are bactericidal antibiotics with broad spectrum antimicrobial activity and many advantageous pharmacokinetic properties including high oral bioavailability and large volume of distribution  (
         <a class="graphic graphic_table graphicRef72974" href="/z/d/graphic/72974.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Mechanism of action'
         </a>
         above and
         <a class="local">
          'Pharmacokinetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Spectrum of activity
         </strong>
         − The spectrum of activity includes aerobic, enteric gram-negative bacilli (eg,
         <em>
          Escherichia coli
         </em>
         ) and many common respiratory pathogens, including atypical bacteria. Some fluoroquinolones are also active against
         <em>
          Pseudomonas
         </em>
         species, selected gram-positive organisms, anaerobes, and mycobacteria. (See
         <a class="local">
          'Spectrum of activity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         primarily targets gram-negative bacilli, including
         <em>
          Pseudomonas
         </em>
         <em>
          aeruginosa
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          Levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         , and
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          delafloxacin
         </a>
         have increased activity against gram-positive organisms (eg,
         <em>
          Streptococcus pneumoniae
         </em>
         ) and reduced activity against
         <em>
          P. aeruginosa
         </em>
         when compared with
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          Moxifloxacin
         </a>
         additionally has activity against some anaerobes and is most active against mycobacteria compared with other fluoroquinolones.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          Delafloxacin
         </a>
         (the newest fluoroquinolone) also has activity against anaerobes and is the only fluoroquinolone with reliable activity against methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         (MRSA). However, clinical experience with delafloxacin is limited.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimicrobial resistance
         </strong>
         − Resistance to fluoroquinolones is growing worldwide and is commonly reported in most target bacteria, with the exceptions of
         <em>
          S. pneumoniae, Haemophilus influenzae
         </em>
         , and
         <em>
          Moraxella catarrhalis.
         </em>
         Resistance mechanisms can be chromosomally encoded or plasmid mediated. Plasmid-mediated mechanisms are almost always associated with resistance to other antibiotics. (See
         <a class="local">
          'Antimicrobial resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reserving use for complicated infections
         </strong>
         − Because of rising resistance rates, growing knowledge of potentially serious adverse effects (including
         <em>
          Clostridioides
         </em>
         <em>
          difficile
         </em>
         infection), and drug interactions, use of fluoroquinolones is generally reserved for complicated infections in which the benefits of use clearly outweigh the risks. (See
         <a class="local">
          'Benefits and risks of use'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoiding use in children and pregnant and lactating women
         </strong>
         − Fluoroquinolones should generally be avoided in pregnant women, lactating women, and children, unless a safer alternative is not available. This avoidance is due to the potential for musculoskeletal toxicity in developing fetuses and children. (See
         <a class="local">
          'Pregnancy and breastfeeding'
         </a>
         above and
         <a class="local">
          'Children'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         − The most common adverse effects are mild and involve the gastrointestinal tract (eg, nausea) and central nervous system (eg, headache and dizziness). Less common but potentially severe adverse effects include QT interval prolongation, tendinopathies, dysglycemia, and putatively retinal detachment and aortic aneurysm or dissection. (See
         <a class="local">
          'Adverse effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug interactions
         </strong>
         − Fluoroquinolones interact with multiple other medications. Additional detail can be found in the Lexicomp database and
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Coadministration of other medications that prolong the QT interval should be avoided because of the risk of potentially fatal arrhythmias  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dairy, antacids, multivitamins containing zinc, certain medications (eg,
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          sucralfate
         </a>
         ), and other sources of divalent cations can substantially decrease oral absorption. Concurrent use should be avoided or these substances should be given several hours apart from the fluoroquinolone in order to avoid their interaction.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          US Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm (Accessed on May 26, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tandan M, Cormican M, Vellinga A. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: A systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents 2018; 52:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guh AY, Adkins SH, Li Q, et al. Risk Factors for Community-Associated Clostridium difficile Infection in Adults: A Case-Control Study. Open Forum Infect Dis 2017; 4:ofx171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasiri MJ, Goudarzi M, Hajikhani B, et al. Clostridioides (Clostridium) difficile infection in hospitalized patients with antibiotic-associated diarrhea: A systematic review and meta-analysis. Anaerobe 2018; 50:32.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics (Accessed on May 18, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe T, Fujikawa K, Harada S, et al. Reproductive toxicity of the new quinolone antibacterial agent levofloxacin in rats and rabbits. Arzneimittelforschung 1992; 43:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takayama S, Watanabe T, Akiyama Y, et al. Reproductive toxicity of ofloxacin. Arzneimittelforschung 1986; 36:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shakibaei M, Baumann-Wilschke I, Rücker M, Stahlmann R. Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones. Arch Toxicol 2002; 75:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aboubakr M, Elbadawy M, Soliman A, El-Hewaity M. Embryotoxic and teratogenic effects of norfloxacin in pregnant female albino rats. Adv Pharmacol Sci 2014; 2014:924706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bar-Oz B, Moretti ME, Boskovic R, et al. The safety of quinolones--a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2009; 143:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acar S, Keskin-Arslan E, Erol-Coskun H, et al. Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: A systematic review and meta-analysis. Reprod Toxicol 2019; 85:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2018-2021 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.903.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orenstein DM, Pattishall EN, Noyes BE, et al. Safety of ciprofloxacin in children with cystic fibrosis. Clin Pediatr (Phila) 1993; 32:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009; 33:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pichichero ME, Arguedas A, Dagan R, et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis 2005; 41:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007; 26:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley JS, Kauffman RE, Balis DA, et al. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics 2014; 134:e146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheikh S, Alvi U, Soliven B, Rezania K. Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update. J Clin Med 2021; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf 2011; 34:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correia S, Poeta P, Hébraud M, et al. Mechanisms of quinolone action and resistance: where do we stand? J Med Microbiol 2017; 66:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mant TG. Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing. Am J Med 1992; 92:26S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lode H, Höffken G, Boeckk M, et al. Quinolone pharmacokinetics and metabolism. J Antimicrob Chemother 1990; 26 Suppl B:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nightingale CH. Overview of the pharmacokinetics of fleroxacin. Am J Med 1993; 94:38S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flor S. Pharmacokinetics of ofloxacin. An overview. Am J Med 1989; 87:24S.
          </a>
         </li>
         <li class="breakAll">
          Baxdela (delafloxacin), for oral use, for injection, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf (Accessed on August 14, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41:2256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sörgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors, Part 1: Basic chemistry and gastrointestinal disposition. Am J Med 1993; 94:44S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staib AH, Beermann D, Harder S, et al. Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule). Am J Med 1989; 87:66S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radandt JM, Marchbanks CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 1992; 14:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ott SR, Allewelt M, Lorenz J, et al. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008; 36:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sillerström E, Wahlund E, Nord CE. In vitro activity of ABT-492 against anaerobic bacteria. J Chemother 2004; 16:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 1999; 2:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006; 12:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Périchon B, Courvalin P, Galimand M. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob Agents Chemother 2007; 51:2464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hooper DC, Jacoby GA. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance. Cold Spring Harb Perspect Med 2016; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacoby GA, Strahilevitz J, Hooper DC. Plasmid-mediated quinolone resistance. Microbiol Spectr 2014; 2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chávez-Jacobo VM, Hernández-Ramírez KC, Romo-Rodríguez P, et al. CrpP Is a Novel Ciprofloxacin-Modifying Enzyme Encoded by the Pseudomonas aeruginosa pUM505 Plasmid. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci 2015; 1354:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tam VH, Louie A, Fritsche TR, et al. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis 2007; 195:1818.
          </a>
         </li>
         <li class="breakAll">
          Mylan Zagam discontinued: Charges total $4.7 mil in fiscal third quarter. In: "The Pink Sheet" vol. 63 no. 6. F-D-C Reports, Inc. Chevy Chase, Maryland 2001. p.29.
         </li>
         <li class="breakAll">
          Glaxo withdraws Raxar following seven fatal cardiovascular AEs. "The Pink Sheet", November 1, 1999, p.17.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 Suppl 2:S144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassetti M, Righi E, Pecori D, Tillotson G. Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. Future Microbiol 2018; 13:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodise T, Corey R, Hooper D, Cammarata S. Safety of Delafloxacin: Focus on Adverse Events of Special Interest. Open Forum Infect Dis 2018; 5:ofy220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavanagh K, Pan J, Marwick C, et al. Cumulative and temporal associations between antimicrobial prescribing and community-associated Clostridium difficile infection: population-based case-control study using administrative data. J Antimicrob Chemother 2017; 72:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guh AY, Mu Y, Baggs J, et al. Trends in incidence of long-term-care facility onset Clostridium difficile infections in 10 US geographic locations during 2011-2015. Am J Infect Control 2018; 46:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dingle KE, Didelot X, Quan TP, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis 2017; 17:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011; 9:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schloss M, Becak D, Tosto ST, Velayati A. A Case of Levoﬂoxacin-Induced Hepatotoxicity. Am J Case Rep 2018; 19:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qutrio Baloch Z, Raza MA, Abbas SA, Bukhari S. Ciprofloxacin-induced Hepatotoxicity in a Healthy Young Adult. Cureus 2017; 9:e1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unger C, Al-Jashaami LS. Ciprofloxacin Exposure Leading to Fatal Hepatotoxicity: An Unusual Correlation. Am J Case Rep 2016; 17:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueira-Coelho J, Pereira O, Picado B, et al. Acute hepatitis associated with the use of levofloxacin. Clin Ther 2010; 32:1733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nibell O, Svanström H, Inghammar M. Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study. Clin Infect Dis 2022; 74:2152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paterson JM, Mamdani MM, Manno M, et al. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ 2012; 184:1565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alshammari TM, Larrat EP, Morrill HJ, et al. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study. Am J Health Syst Pharm 2014; 71:37.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions. https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics-risks-mental-health-and-low-blood-sugar-adverse (Accessed on May 18, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etminan M, Brophy JM, Samii A. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology 2014; 83:1261.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf (Accessed on August 16, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morales D, Pacurariu A, Slattery J, et al. Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy. JAMA Neurol 2019; 76:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng JZ, Sodhi M, Etminan M, Carleton BC. Fluoroquinolone Use and Risk of Carpal Tunnel Syndrome: A Pharmacoepidemiologic Study. Clin Infect Dis 2017; 65:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions. Drug Saf 2003; 26:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halliwell RF, Davey PG, Lambert JJ. Antagonism of GABAA receptors by 4-quinolones. J Antimicrob Chemother 1993; 31:457.
          </a>
         </li>
         <li class="breakAll">
          Hori S, Shimada S. Effects of quinolones on the central nervous system. In: Quinolone antimicrobial agents, 2nd ed, Hooper DC, Wolfson JS (Eds), American Society for Microbiology, Washington, DC 1993. p.513.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: A systematic review. Neurology 2015; 85:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sodhi M, Sheldon CA, Carleton B, Etminan M. Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study. Neurology 2017; 89:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang J, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou HW, Wang JL, Chang CH, et al. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis 2015; 60:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inghammar M, Svanström H, Melbye M, et al. Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. BMJ 2016; 352:i843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorelik E, Masarwa R, Perlman A, et al. Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis. Drug Saf 2019; 42:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mogle BT, Steele JM, Thomas SJ, et al. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother 2018; 73:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother 1996; 37 Suppl A:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open 2015; 5:e010077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CC, Lee MT, Chen YS, et al. Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. JAMA Intern Med 2015; 175:1839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh S, Nautiyal A. Aortic Dissection and Aortic Aneurysms Associated with Fluoroquinolones: A Systematic Review and Meta-Analysis. Am J Med 2017; 130:1449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018; 360:k678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CC, Lee MG, Hsieh R, et al. Oral Fluoroquinolone and the Risk of Aortic Dissection. J Am Coll Cardiol 2018; 72:1369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etminan M, Sodhi M, Ganjizadeh-Zavareh S, et al. Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation. J Am Coll Cardiol 2019; 74:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zabraniecki L, Negrier I, Vergne P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol 1996; 23:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Linden PD, Sturkenboom MC, Herings RM, et al. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163:1801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melhus A, Apelqvist J, Larsson J, Eneroth M. Levofloxacin-associated Achilles tendon rupture and tendinopathy. Scand J Infect Dis 2003; 35:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36:1404.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics (Accessed on May 18, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise BL, Peloquin C, Choi H, et al. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 2012; 125:1228.e23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger I, Goodwin I, Buncke GM. Fluoroquinolone-Associated Tendinopathy of the Hand and Wrist: A Systematic Review and Case Report. Hand (N Y) 2017; 12:NP121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Linden PD, van de Lei J, Nab HW, et al. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 1999; 48:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sode J, Obel N, Hallas J, Lassen A. Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study. Eur J Clin Pharmacol 2007; 63:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baik S, Lau J, Huser V, McDonald CJ. Association between tendon ruptures and use of fluoroquinolone, and other oral antibiotics: a 10-year retrospective study of 1 million US senior Medicare beneficiaries. BMJ Open 2020; 10:e034844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolon B. Mini-Review: Toxic Tendinopathy. Toxicol Pathol 2017; 45:834.
          </a>
         </li>
         <li class="breakAll">
          Stahlmann R. Effects on connective structures. In: Quinolone Antimicrobial Agents, Hooper DC, Rubinstein E (Eds), 2003. p.441.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam D. Use of quinolones in pediatric patients. Rev Infect Dis 1989; 11 Suppl 5:S1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaad UB, Wedgwood J. Lack of quinolone-induced arthropathy in children. J Antimicrob Chemother 1992; 30:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou HW, Wang JL, Chang CH, et al. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis 2013; 57:971.
          </a>
         </li>
         <li class="breakAll">
          Bristol Tequin labeling update includes new indication, glucose warning. In: "The Pink Sheet" vol. 64 no. 43. F-D-C Reports, Inc. Chevy Chase, Maryland 2002. p.14.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hypoglycemia and hyperglycemia with fluroroquinolones. Med Lett Drugs Ther 2003; 45:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005; 41:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aspinall SL, Good CB, Jiang R, et al. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 2009; 49:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etminan M, Forooghian F, Brophy JM, et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA 2012; 307:1414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasternak B, Svanström H, Melbye M, Hviid A. Association between oral fluoroquinolone use and retinal detachment. JAMA 2013; 310:2184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapoor KG, Hodge DO, St Sauver JL, Barkmeier AJ. Oral fluoroquinolones and the incidence of rhegmatogenous retinal detachment and symptomatic retinal breaks: a population-based study. Ophthalmology 2014; 121:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raguideau F, Lemaitre M, Dray-Spira R, Zureik M. Association Between Oral Fluoroquinolone Use and Retinal Detachment. JAMA Ophthalmol 2016; 134:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo SC, Chen YT, Lee YT, et al. Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study. Clin Infect Dis 2014; 58:197.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm (Accessed on April 02, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayashi N, Nakata Y, Yazaki A. New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones with various substituents at position 1. Antimicrob Agents Chemother 2004; 48:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dawe RS, Ferguson J, Ibbotson S, et al. Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin. Photochem Photobiol Sci 2018; 17:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ball P, Mandell L, Patou G, et al. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004; 23:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iannini P, Mandell L, Patou G, Shear N. Cutaneous adverse events and gemifloxacin: observations from the clinical trial program. J Chemother 2006; 18:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farid S, Mahmood M, Abu Saleh OM, et al. Clinical Manifestations and Outcomes of Fluoroquinolone-Related Acute Interstitial Nephritis. Mayo Clin Proc 2018; 93:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golomb BA, Koslik HJ, Redd AJ. Fluoroquinolone-induced serious, persistent, multisymptom adverse effects. BMJ Case Rep 2015; 2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother 2001; 35:1540.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Fluoroquinolone safety labeling changes, April 4, 2017. https://www.fda.gov/media/104060/download (Accessed on May 14, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robson RA. The effects of quinolones on xanthine pharmacokinetics. Am J Med 1992; 92:22S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stahlmann R, Schwabe R. Safety profile of grepafloxacin compared with other fluoroquinolones. J Antimicrob Chemother 1997; 40 Suppl A:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007; 45:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dooley K, Flexner C, Hackman J, et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 2008; 52:4037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Israel DS, Stotka J, Rock W, et al. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin Infect Dis 1996; 22:251.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 490 Version 76.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : US Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm (Accessed on May 26, 2016).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29702230" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: A systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29732377" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Risk Factors for Community-Associated Clostridium difficile Infection in Adults: A Case-Control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29408016" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clostridioides (Clostridium) difficile infection in hospitalized patients with antibiotic-associated diarrhea: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29408016" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clostridioides (Clostridium) difficile infection in hospitalized patients with antibiotic-associated diarrhea: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1622435" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Reproductive toxicity of the new quinolone antibacterial agent levofloxacin in rats and rabbits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3465327" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Reproductive toxicity of ofloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11876506" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24639869" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Embryotoxic and teratogenic effects of norfloxacin in pregnant female albino rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19181435" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The safety of quinolones--a meta-analysis of pregnancy outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30738954" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27940800" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The Use of Systemic and Topical Fluoroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9402381" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Quinolone arthropathy in animals versus children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9402381" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Quinolone arthropathy in animals versus children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8403750" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Safety of ciprofloxacin in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18835137" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16028153" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17901792" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24918220" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33917535" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21879778" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9293187" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : DNA gyrase, topoisomerase IV, and the 4-quinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28504927" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Mechanisms of quinolone action and resistance: where do we stand?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1316066" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2124212" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Quinolone pharmacokinetics and metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8452184" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Overview of the pharmacokinetics of fleroxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2603892" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pharmacokinetics of ofloxacin. An overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2603892" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pharmacokinetics of ofloxacin. An overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9333057" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8383920" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pharmacokinetics of gyrase inhibitors, Part 1: Basic chemistry and gastrointestinal disposition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2589389" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1571442" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18231720" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15330316" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : In vitro activity of ABT-492 against anaerobic bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11504468" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Mechanisms of fluoroquinolone resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17008172" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The worldwide emergence of plasmid-mediated quinolone resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16369542" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17470656" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27449972" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25584197" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Plasmid-mediated quinolone resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29581123" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : CrpP Is a Novel Ciprofloxacin-Modifying Enzyme Encoded by the Pseudomonas aeruginosa pUM505 Plasmid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26190223" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mechanisms of drug resistance: quinolone resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17492598" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17492598" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17492598" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15942881" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Antimicrobial safety: focus on fluoroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19419232" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29764190" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30349845" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Safety of Delafloxacin: Focus on Adverse Events of Special Interest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27999064" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cumulative and temporal associations between antimicrobial prescribing and community-associated Clostridium difficile infection: population-based case-control study using administrative data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29329918" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Trends in incidence of long-term-care facility onset Clostridium difficile infections in 10 US geographic locations during 2011-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28130063" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effects of control interventions on Clostridium difficile infection in England: an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16322603" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : An epidemic, toxin gene-variant strain of Clostridium difficile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21356330" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Clinical and histopathologic features of fluoroquinolone-induced liver injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29523775" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A Case of Levoﬂoxacin-Induced Hepatotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28348936" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Ciprofloxacin-induced Hepatotoxicity in a Healthy Young Adult.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27653941" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Ciprofloxacin Exposure Leading to Fatal Hepatotoxicity: An Unusual Correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21194596" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Acute hepatitis associated with the use of levofloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34537834" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22891208" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24352180" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24352180" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25150290" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25150290" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31034074" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28444196" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Fluoroquinolone Use and Risk of Carpal Tunnel Syndrome: A Pharmacoepidemiologic Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12534327" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8390432" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Antagonism of GABAA receptors by 4-quinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8390432" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Antagonism of GABAA receptors by 4-quinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26400582" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Seizures as adverse events of antibiotic drugs: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28754842" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11125032" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22591294" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Azithromycin and the risk of cardiovascular death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25409476" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, andβ-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26920666" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30368737" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29425340" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Clinical review of delafloxacin: a novel anionic fluoroquinolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8737135" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26582407" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26436523" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28739200" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Aortic Dissection and Aortic Aneurysms Associated with Fluoroquinolones: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29519881" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30213330" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Oral Fluoroquinolone and the Risk of Aortic Dissection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31514945" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8832995" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Fluoroquinolone induced tendinopathy: report of 6 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12039823" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Fluoroquinolones and risk of Achilles tendon disorders: case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12912715" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14606622" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Levofloxacin-associated Achilles tendon rupture and tendinopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12766835" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Fluoroquinolone-associated tendinopathy: a critical review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12766835" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Fluoroquinolone-associated tendinopathy: a critical review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23026288" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28366020" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Fluoroquinolone-Associated Tendinopathy of the Hand and Wrist: A Systematic Review and Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10510157" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Achilles tendinitis associated with fluoroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17334751" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33371012" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Association between tendon ruptures and use of fluoroquinolone, and other oral antibiotics: a 10-year retrospective study of 1 million US senior Medicare beneficiaries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28553748" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Mini-Review: Toxic Tendinopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28553748" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Mini-Review: Toxic Tendinopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2672245" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Use of quinolones in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1490915" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Lack of quinolone-induced arthropathy in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23948133" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23948133" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12888740" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Hypoglycemia and hyperglycemia with fluroroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16206101" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Glucose homeostasis abnormalities associated with use of gatifloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16510739" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Outpatient gatifloxacin therapy and dysglycemia in older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19545207" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Severe dysglycemia with the fluoroquinolones: a class effect?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22474205" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Oral fluoroquinolones and the risk of retinal detachment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24281462" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Association between oral fluoroquinolone use and retinal detachment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24480710" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Oral fluoroquinolones and the incidence of rhegmatogenous retinal detachment and symptomatic retinal breaks: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26967005" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Association Between Oral Fluoroquinolone Use and Retinal Detachment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24170197" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24170197" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14982767" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones with various substituents at position 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29721574" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10064255" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Fluoroquinolone toxicity profiles: a review focusing on newer agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15120718" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16572887" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Cutaneous adverse events and gemifloxacin: observations from the clinical trial program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29157532" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Clinical Manifestations and Outcomes of Fluoroquinolone-Related Acute Interstitial Nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26438672" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Fluoroquinolone-induced serious, persistent, multisymptom adverse effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11793615" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Peripheral neuropathy associated with fluoroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11793615" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Peripheral neuropathy associated with fluoroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1580270" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : The effects of quinolones on xanthine pharmacokinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9484877" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Safety profile of grepafloxacin compared with other fluoroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17879915" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18765687" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8838180" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
